NK92MI

NK92MI is an interleukin-2 (IL-2)-independent natural killer (NK) cell line derived from the parental NK-92 line. It was engineered by transfection with a retroviral vector containing the human IL-2 gene, which allows for autocrine growth and eliminates the requirement for exogenous IL-2 supplementation. NK92MI cells retain the potent cytotoxic characteristics of the parental line, including the expression of activating receptors such as NKp30, NKp44, and NKG2D, while lacking most inhibitory killer cell immunoglobulin-like receptors (KIRs). This cell line serves as a versatile platform for adoptive immunotherapy, particularly in the development of chimeric antigen receptor (CAR)-modified NK cells (CAR-NK) targeting various malignancies. In clinical applications, the cells are typically irradiated to ensure safety by preventing permanent engraftment or malignant transformation while maintaining their immediate tumoricidal activity.

Other names

NK-92MI cell lineNK92MI cell lineNK 92MI cell lineIL-2-independent NK-92 cellsIL2-independent NK-92 cellsIL 2-independent NK-92 cells